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Available online 12 December 2015Skin ﬁbroblasts were obtained from a 59-year-oldwoman diagnosedwith frontotemporal dementia. The disease
is caused by a R406Wmutation in microtubule-associated protein tau (MAPT). Induced pluripotent stem cells
(iPSCs) were established by electroporation with episomal plasmids containing hOCT4, hSOX2, hKLF2, hL-MYC,
hLIN-28 and shP53. iPSCs were free of genomically integrated reprogramming genes, contained the expected
c.1216C N T substitution in exon 13 of theMAPT gene, expressed the expected pluripotency markers, displayed
in vitro differentiation potential to the three germ layers and had normal karyotype. The iPSC line may be useful
for studying hereditary frontotemporal dementia and TAU pathology in vitro.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Resource table
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Fibroblasts were obtained from a 59-year old woman heterozygous
for a R406W mutation in microtubule-associated protein tau (MAPT).
The patient was clinically diagnosed with frontotemporal dementia at
age 52, displaying atrophy of the temporal lobes onmagnetic resonance
imaging and reduction in glucose metabolism bilaterally in the
temporal pole andadjacent lateral andmedial temporal cortex including
the anterior sections of the hippocampi and the amygdalae using 18-
ﬂuoro-deoxyglucose positron emission tomography (Lindquist et al.,
2008). Reprogramming was performed by electroporation with three
episomal plasmids containing hOCT4 with or without a short hairpin to
TP53 (shp53), hSOX2 and hKLF4, and hL-MYC and hLIN28 (Okita et al.,
2011). This method had previously been used to establish integration-
free iPSC from an 18-year old healthy male (Rasmussen et al., 2014).
Four weeks after reprogramming, an average of 64 colonies per
1 × 105 ﬁbroblasts (0.06%) emerged with the inclusion of shp53, where-
as, no colonies were observed without shp53. Integration analysis with
plasmid-speciﬁc primers showed thathOCT4, hSOX2 and hLIN28, present
on each of the three plasmids, had not integrated into the genome
(Fig. 1A) and sequencing conﬁrmed the presence of a c.1216C N T substi-
tution in one of the alleles of exon 13 in theMAPT gene corresponding to
a R406W mutation (Fig. 1B). Pluripotency analysis showed that tran-
scription from the endogenous pluripotency genes NANOG, POU5F1
(OCT4), TDGF1, DNMT3B, GABRB3 and GDF3 was between 100 andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A. Integration analysis. Quantitative PCR (qPCR) on genomic DNA from H237 C3 induced pluripotent stem cells (iPSC), ﬁbroblasts and a pool of ﬁbroblasts electroporated with
episomal plasmids (positive control) with plasmid-speciﬁc primers of hOCT4, hSOX2, and hLIN28. Data is shown as the fold change (2−ΔΔCt) with GAPDH and ﬁbroblasts as references.
B. Sequencing of mutation. Sequencing of exon 13 of theMAPT gene in H237 C3 induced pluripotent stem cells showing a c.1216C N T substitution in one of the alleles marked with a red
arrow. C. Pluripotency expression analysis. Quantitative reverse-transcriptase PCR (qRT-PCR) expression analyses on cDNA fromH237 C3 induced pluripotent stemcells (iPSC), ﬁbroblasts
and the iPSC line BIONi010-A (Rasmussen et al., 2014) as a positive control with the endogenous pluripotency genes NANOG, POU5F1 (OCT4), TDGF1, DNMT3B, GABRB3 and GDF3. Relative
expression is shown as the fold change (2−ΔΔCt) with GAPDH and ﬁbroblasts as references. D. Immunoﬂuorescence staining. Immunocytochemical detection of H237 C3 induced plu-
ripotent stem cells with the pluripotencymarkers OCT3/4, TRA1-81, NANOG, TRA1-60, SSEA3, and SSEA4. Scale bars correspond to 400 μm. E. In vitrodifferentiation. Immunocytochemical
staining of plated embryoid bodies (EBs) fromH237 C3 induced pluripotent stem cells on day 28with smoothmuscle actin (SMA), alpha-fetoprotein (AFP) and betaIIItubulin (TUJI). Scale
bars correspond to 100 μm. F. Karyotyping. Representative karyotype of H237 C3 induced pluripotent stem cells.
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Fig. 1 (continued).
77M.A. Rasmussen et al. / Stem Cell Research 16 (2016) 75–7810,000 times upregulated compared with ﬁbroblasts (Fig. 1C) and
immunocytochemical (ICC) analysis demonstrated the presence of the
pluripotency markers OCT4, NANOG, TRA1-60, TRA1-81, SSEA3 and
SSEA4 at the protein level (Fig. 1D). Finally, in vitro differentiation
followed by ICC analysis with the mesodermal marker smooth muscle
actin (SMA), the endodermal marker alpha-feto protein (AFP) and the
ectodermal marker beta-III-Tubulin (TUJI) demonstrated the differenti-
ation potential into all three germ layers (Fig. 1E).
3. Materials and methods
Unless otherwise stated, consumables and reagents were purchased
from Sigma-Aldrich, St. Louis, MO, USA.
3.1. Establishment of iPSC
A skin biopsy was obtained from a 59-year old woman carrying a
R406W mutation in MAPT. The study was approved by the regional
scientiﬁc ethical committee in the Capital Region of Denmark (RH),
andwritten informed consent was obtained from the donor. Fibroblasts
were cultured in ﬁbroblast medium, consisting of Dulbecco's Modiﬁed
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and 1% penicillin and streptomycin (Pen/Strep). 1 × 105 ﬁbroblasts were electroporated with a total of 1 μg of
episomal plasmids containing hOCT4 with or without a short hairpin
to TP53 (shp53; Addgene plasmids 27077 and 27076, respectively),
hSOX2 and hKLF4 (Addgene plasmid 27078), and hL-MYC and hLIN28
(Addgene plasmid 27080; Okita et al., 2011) and cultured in ﬁbroblast
medium. Electroporation was carried out using a Neon™ electropora-
tion device with two pulses at 1200 V for 20 ms (Life Technologies,
Carlsbad, CA, USA). One week after electroporation, the ﬁbroblasts were
trypsinized and split 1:2 onto hESC-qualiﬁed Matrigel-coated dishes
(BD Biosciences, Franklin Lakes, NJ, USA) and cultured in mTeSR1 medi-
um (Stem Cell Technologies, Vancouver, BC, Canada) in 5% O2, 5% CO2 in
N2. After four weeks, primary iPSC colonies were dissected out manually,
transferred to new Matrigel-coated dishes, and cultured in mTeSR1.
The iPSC lines were split 1:6 every 5–6 days with Dispase (Stem Cell
Technologies, Vancouver, BC, Canada). At passage 10, the iPSC lines
were harvested for subsequent analyses or frozen in liquid nitrogen in
mTeSR1 containing 10% DMSO.
3.2. Integration analysis
DNA was puriﬁed from iPSCs, ﬁbroblasts and a pool of ﬁbroblasts
electroporated with episomal plasmids as a positive control using the
DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). qPCR analysis
Table 1
Antibodies used for immunocytochemistry.
Antibody and
host species
Dilution Company and
catalog number
Pluripotency Rabbit anti-NANOG 1:500 Peprotech, 500-P236
Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rat anti-SSEA3 1:100 Biolegend, 330302
Mouse anti-SSEA4 1:100 Biolegend, 330402
Mouse anti-Tra-1-81 1:200 Biolegend, 330702
Mouse anti-Tra-1-60 1:200 Biolegend, 330602
In vitro differentiation Mouse anti-Smooth
muscle actin (SMA)
1:500 DAKO, M0851
Rabbit anti-Alpha-1-
fetoprotein (AFP)
1:500 DAKO, A0008
Mouse anti-Beta-III-
tubulin (TUJI)
1:4000 Sigma-Aldrich, T8660
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which are speciﬁc to the three plasmids (Okita et al., 2011) and data
was analyzed using the 2−ΔΔCt method relative to GAPDH with ﬁbro-
blasts as a reference (set to 1).
3.3. Pluripotency expression analysis
Total RNA was puriﬁed from iPSCs, ﬁbroblasts and the iPSC line
BIONi010-A (Rasmussen et al., 2014) as a positive control using RNeasy
mini kit (Qiagen, Hilden, Germany). Conversion to cDNAwas performed
with RevertAid First Strand cDNA synthesis kit (Thermo Scientiﬁc,
Waltham, MA, USA). qPCR analysis was carried out using the TaqMan
primers GAPDH Hs03929097_g1, NANOG Hs02387400_g1, POU5F1
Hs00999632_g1, TDGF1 Hs02339497_g1, DMNT3B Hs00171876_m1,
GABRB3 Hs00241459_m1 and GDF3 Hs00220998_m1 (Thermo Scientiﬁc,
Waltham, MA, USA; International Stem Cell Banking Initiative). Data
was analyzed using the 2−ΔΔCt method relative to GAPDH with ﬁbro-
blasts as a reference (set to 1).
3.4. Sequencing of mutation
Sanger sequencing of exon 13 of theMAPT genewas carried out in an
ABI PRISM 310 Genetic Analyzer using the primers MAPT_Ex13Fw
ctggtctttctctggcactt and MAPT_Ex13Rv accaattaaccgaactgcg
(NM_001123066.3; Lindquist et al., 2008).
3.5. Immunoﬂuorescence staining
iPSCs were ﬁxed with 4% paraformaldehyde (PFA) in PBS for 15min
and stained by standard immunoﬂuorescence procedures. The primary
antibodies (Table 1) were visualized with the secondary antibodies
Alexa 488 or Alexa 594 diluted 1:400 (Life technologies, Carlsbad, CA,
USA) and counterstained with Hoechst bisbenzimide 33258. Images
were acquired on a Leica DMRB-ﬂuorescence microscope (Leica
Microsystems, Wetzlar, Germany).
3.6. In vitro differentiation
Embryoid body (EB) formation was performed by transferring
Dispase-treated clumps of iPSC to ultra-low attachment plates (Corning,
Corning, NY, USA) in mTeSR1. After 2 days of culture, the medium was
changed to DMEM/F12 containing 20% knockout serum replacement
(Life Technologies, Carlsbad, CA, USA), 1× non-essential amino acid,
2 mM L-glutamine, 0.1 mM 2-mercaptoethanol and 1% pen/strep.
After 7 days, the EBs were plated on 0.1% gelatin-coated culture dishes
and cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine
and 1% pen/strep for up to three weeks. The cells were ﬁxed for 15 min
in 4% PFA for ICC analyses with the antibodies TUJI, SMA and AFP
(Table 1).
3.7. Karyotyping
iPSCs and ﬁbroblasts were treated for 45 min with KaryoMAX
colcemid (Life Technologies, Carlsbad, CA, USA) and harvested in freshﬁxative containing 25% acetic acid and 75% methanol. Karyotyping
was performed on G-banded metaphase chromosomes using standard
cytogenetic procedures.
4. Veriﬁcation and authentication
Karyotyping was performed at the Center for Applied Human
Molecular Genetics, Kennedy Center, Glostrup, Denmark. At least 10
metaphases were analyzed per sample with an approximate resolution
of 550 to 600 bands per haploid genome. The results showed a normal
46, XX karyotype, free of any discernible abnormalities (Fig. 1F). iPSC
line identity and purity was conﬁrmed by sequencing of the MAPT
gene (Fig. 1B) and ICC with pluripotency markers (Fig. 1D).
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